Advisers to the U.S. Food and Drug Administration on Thursday will discuss and vote on whether to recommend targeting one of the currently dominant XBB coronavirus variants in updated COVID-19 shots being developed for a fall vaccination campaign.
https://www.pharmalive.com/wp-content/uploads/2023/04/ReutersModernavax4-12-2023.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-06-15 06:04:512023-06-15 09:11:39U.S. FDA panel to weigh makeup of next COVID vaccine
